The pivotal discovery that nitric oxide was a key signaling molecule in the cardiovascular
system resulted in the awarding of the Nobel prize in 1998 to the persons who discovered its …

Early reports of inhaled nitric oxide (iNO) therapy in near-term and term newborns with
hypoxemic respiratory failure and persistent pulmonary hypertension described marked …

Inhaled nitric oxide is a powerful therapeutic used in neonatology. Its use is evidenced-
based for term and near-term infants with persistent pulmonary hypertension; however, it is …

On the basis of best available evidence, learned authorities do not recommend routine use
of inhaled nitric oxide (iNO) in preterm infants in hypoxic respiratory failure (1). Yet published …

Nitric oxide, an important signaling molecule with multiple regulatory effects throughout the
body, is an important tool for the treatment of full-term and late-preterm infants with persistent …

Inhaled nitric oxide (iNO) is a pulmonary vasodilator that plays a major role in regulating
vascular muscle tone. It has emerged as a treatment for hypoxemic respiratory failure in …

Inhaled nitric oxide (iNO) is a well-established frontline therapy for term infants with
persistent pulmonary hypertension of the newborn (PPHN). PPHN typically occurs in full …

Inhaled nitric oxide (INO) is a novel selective pulmonary vasodilator without effects on the
systemic circulation. Initial case studies of near-term newborn infants with hypoxic …

Inhaled nitric oxide (INO) is a novel selective pulmonary vasodilator without significant
effects on the systemic circulation. Initial case studies of near-term newborn infants with …

Three decades since the first pilot studies showed improvement in oxygenation with the use
of inhaled nitric oxide (iNO) in term neonates with persistent pulmonary hypertension of the …